Knowledge graph · Drug
Ibritumomab Tiuxetan
monoclonal antibody
- Identifier
- CI-DRUG-00000711
- Entity page
- /drug/ibritumomab-tiuxetan ↗
- Edges
- 46
- Neighbours
- 9 cancers10 trials6 approvals
- Drawn
- 25 of 25 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Ibritumomab Tiuxetan approved for …APPROVED_FOR8 of 7 | ||||||||
| → approved for | B-Cell Non-Hodgkin Lymphomahematologic_malignancy | supports | FDA ORIG | B-Cell Non-Hodgkin Lymphoma | 1 | Regulatory | openfda | graph → |
| → approved for | Health Canada · CA · 2018Marketed in Canada as ZEVALIN (DIN 02328674) under ATC V10XX02 IBRITUMOMAB TIUXETAN (90Y). Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | |||||||